Literature DB >> 27308389

The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Asaf Shilo1, Zahava Siegfried1, Rotem Karni1.   

Abstract

In past decades, cancer research has focused on genetic alterations that are detected in malignant tissues and contribute to the initiation and progression of cancer. These changes include mutations, copy number variations, and translocations. However, it is becoming increasingly clear that epigenetic changes, including alternative splicing, play a major role in cancer development and progression. There are relatively few studies on the contribution of alternative splicing and the splicing factors that regulate this process to cancer development and progression. Recently, multiple studies have revealed altered splicing patterns in cancers and several splicing factors were found to contribute to tumor development. Studies using high-throughput genomic analysis have identified mutations in components of the core splicing machinery and in splicing factors in several cancers. In this review, we will highlight new findings on the role of alternative splicing and its regulators in cancer initiation and progression, in addition to novel approaches to correct oncogenic splicing.

Entities:  

Keywords:  SR proteins; alternative splicing; cancer; hnRNPs

Year:  2014        PMID: 27308389      PMCID: PMC4905244          DOI: 10.4161/23723548.2014.970955

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN: 2372-3556


  193 in total

1.  hnRNP B1 expression in benign and malignant lung disease.

Authors:  D R J Snead; B Perunovic; N Cullen; M Needham; D P Dhillon; H Satoh; H Kamma
Journal:  J Pathol       Date:  2003-05       Impact factor: 7.996

2.  Human hnRNP protein A1 gene expression. Structural and functional characterization of the promoter.

Authors:  G Biamonti; M T Bassi; L Cartegni; F Mechta; M Buvoli; F Cobianchi; S Riva
Journal:  J Mol Biol       Date:  1993-03-05       Impact factor: 5.469

Review 3.  Shuttling SR proteins: more than splicing factors.

Authors:  Laure Twyffels; Cyril Gueydan; Véronique Kruys
Journal:  FEBS J       Date:  2011-08-24       Impact factor: 5.542

4.  Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors.

Authors:  W Jin; I E McCutcheon; G N Fuller; E S Huang; G J Cote
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

5.  Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.

Authors:  Takeshi Fukuhara; Takamitsu Hosoya; Saki Shimizu; Kengo Sumi; Takako Oshiro; Yoshiyuki Yoshinaka; Masaaki Suzuki; Naoki Yamamoto; Leonore A Herzenberg; Leonard A Herzenberg; Masatoshi Hagiwara
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-13       Impact factor: 11.205

6.  The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.

Authors:  G Merdzhanova; S Gout; M Keramidas; V Edmond; J-L Coll; C Brambilla; E Brambilla; S Gazzeri; B Eymin
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

7.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

8.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors:  Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

Review 9.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

10.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

View more
  19 in total

1.  An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells.

Authors:  Mohammad B Uddin; Kartik R Roy; Salman B Hosain; Sachin K Khiste; Ronald A Hill; Seetharama D Jois; Yunfeng Zhao; Alan J Tackett; Yong-Yu Liu
Journal:  Biochem Pharmacol       Date:  2018-12-19       Impact factor: 5.858

Review 2.  The role of RNA alternative splicing in regulating cancer metabolism.

Authors:  Itamar Kozlovski; Zahava Siegfried; Adi Amar-Schwartz; Rotem Karni
Journal:  Hum Genet       Date:  2017-04-20       Impact factor: 4.132

3.  Prognostic alternative splicing signatures and underlying regulatory network in esophageal carcinoma.

Authors:  Zu-Cheng Xie; Hua-Yu Wu; Fu-Chao Ma; Yi-Wu Dang; Zhi-Gang Peng; Hua-Fu Zhou; Gang Chen
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Youli Du; Xiaoou Ma; Dongxu Wang; Yuguang Wang; Tianyu Zhang; Lianjie Bai; Yunlong Liu; Shaosen Chen
Journal:  J Gastrointest Oncol       Date:  2021-10

5.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Defective control of pre-messenger RNA splicing in human disease.

Authors:  Benoit Chabot; Lulzim Shkreta
Journal:  J Cell Biol       Date:  2016-01-04       Impact factor: 10.539

Review 7.  Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.

Authors:  Jung-Chun Lin
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

Review 8.  Integration of mRNP formation and export.

Authors:  Petra Björk; Lars Wieslander
Journal:  Cell Mol Life Sci       Date:  2017-03-17       Impact factor: 9.261

9.  SRSF7 knockdown promotes apoptosis of colon and lung cancer cells.

Authors:  Yu Fu; Yingze Wang
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

Review 10.  Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer.

Authors:  Xiang Zheng; Qiu Peng; Lujuan Wang; Xuemei Zhang; Lili Huang; Jia Wang; Zailong Qin
Journal:  Int J Biol Sci       Date:  2020-07-06       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.